Clinical Trial Spotlight: Options for EGFR Mutation-Positive Patients with T790M Mutation-Negative Acquired Resistance

GRACE Videos and Articles

LCAM 2015

 

Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.

November is Lung Cancer Awareness Month. What are you grateful for?

Watch, read, and then share your own stories of empowerment in our online forum. Your story may inspire others.

[powerpress]

Get more information about the TH4000 Trial.

[ratingwidget post_id=0]

Check out more LCAM videos & posts here.

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation